While more information needs to be learned about COVID-19, it has become clear that poorer outcomes and the risk of mortality in the US population is alarmingly 2.5 times greater in the black population, and 1.2 times greater in Hispanics, than in whites. Henry J. Riordan, Drew Matheson, Natalia E. Drosopoulou and Aman Khera at Worldwide Clinical Trials explores why ensuring diversity in COVID-19 trials is so important, as to date there is no clear present pathophysiological explanations behind the ethnic/racial/minority mortality differences observed with COVID-19.